Literatur
-
1
Abraira C, Duckworth W, McCarren M. et al .
Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
J Diabetes Complications.
2003;
17
314-322
-
2
Abraira C, Duckworth W, McCarren M. et al .
Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
J Diabetes Complications.
2003;
17
314-322
-
3
Bakris G, Viberti G, Weston W M, Heise M, Porter L E, Freed M I.
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
J Hum Hypertens.
2003;
17
7-12
-
4
Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A.
The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
Diabetes Care.
2004;
27
1647-1653
-
5
Choi D, Kim S K, Choi S H. et al .
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
Diabetes Care.
2004;
27
2654-2660
-
6
Fonseca V, Rosenstock J, Patwardhan R, Salzman A.
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
JAMA.
2000;
283
1695-1702
-
7
Freed M I, Ratner R, Marcovina S M. et al .
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
Am J Cardiol.
2002;
90
947-952
-
8
Füchtenbusch M, Standl E, Schatz H.
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Exp Clin Endocrinol Diabetes.
2000;
108
151-163
-
9 Füchtenbusch M, Standl E, Schatz H. Insulinsensitizer: PPARy-Liganden (Glitazone). 3. Auflage Thieme, Stuttgart, New York In: Schatz H (ed) Diabetologie kompakt 2004: 175-187
-
10
Gerstein H C, Yusuf S, Holman R, Bosch J, Pogue J.
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
Diabetologia.
2004;
47
1519-1527
-
11
Gould E, Cobitz A.
Long-term durability of rosiglitazone as monotherapy or in combination therapy in patients with type 2 diabetes (Abstract).
Diabetes.
2002;
51
(Suppl 2)
A98-A99
-
12
Haffner S M, Greenberg A S, Weston W M, Chen H, Williams K, Freed M I.
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Circulation.
2002;
106
679-684
-
13
Home P, Komajda M, Beck-Nielsen H.
Twelve Months Sustained Efficacy of Rosiglitazone Combination Therapy on Ambulatory Blood Pressure (ABP) in People with Type 2 Diabetes Mellitus (Abstract).
Diabetes.
2005;
54
A134
-
14
Home P, Pocock S J, Beck-Nielsen H.
Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in Diabetes (RECORD): An interim analysis of glycaemia at 18 months (Abstract).
Diabetologia.
2004;
47
A262
-
15
Knowler W C, Hamman R F, Edelstein S L. et al .
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.
Diabetes.
2005;
54
1150-1156
-
16
Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y.
Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.
J Clin Endocrinol Metab.
2001;
86
3452-3456
-
17
Lebovitz H E, Kreider M, Freed M I.
Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Diabetes Care.
2002;
25
815-821
-
18
Masoudi F A, Inzucchi S E, Wang Y, Havranek E P, Foody J M, Krumholz H M.
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Circulation.
2005;
111
583-590
-
19
Matthews D R, Charbonnel B H, Hanefeld M, Brunetti P, Schernthaner G.
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
Diabetes Metab Res Rev.
2005;
21
167-174
-
20
Natali A, Baldeweg S, Toschi E. et al .
Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.
Diabetes Care.
2004;
27
1349-1357
-
21
Nauck M A, Matthaei S.
Therapie mit oralen Antidiabetika - Besonderheiten bei koronarer Herzerkrankung.
Dtsch Med Wochenschr.
2005;
130
1091-1096
-
22
Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P.
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
Diabetes Care.
2004;
27
484-490
-
23
Raskin P, Rendell M, Riddle M C, Dole J F, Freed M I, Rosenstock J.
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Diabetes Care.
2001;
24
1226-1232
-
24
Rathmann W, Giani G.
Qualität der Arzneimittelversorgung bei Patienten mit Diabetes mellitus Typ 2 in Deutschland.
Dtsch Med Wochenschr.
2003;
128
1183-1186
-
25
Sidhu J S, Kaposzta Z, Markus H S, Kaski J C.
Effect of rosiglitazone on common carodtid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.
Arterioscler Thromb Vasc Biol.
2004;
24
1-5
-
26
Sutton M, Rendell M, Dandona P. et al .
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.
Diabetes Care.
2002;
25
2058-2064
-
27
Viberti G, Kahn S E, Greene D A. et al .
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Diabetes Care.
2002;
25
1737-1743
-
28 Xiang A H, Peters R K, Kjos S L. Continued protection from diabetes during treatment of the TRIPOD Cohort with pioglitazone (Abstract). Proceedings of the 63rd Annual Meeting of the American Diabetes Association 2003
Univ.-Prof. (emer.) Dr. Helmut Schatz
Universitätsklinikum Bergmannsheil
Buerkle-de-la-Camp-Platz 1
44789 Bochum
Telefon: 0234/3026324
Fax: 0234/3026315
eMail: helmut.schatz@ruhr-uni-bochum.de
